Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00659100 · ClinicalTrials.gov registry record · Phase 3
A Trial to Assess Consumer Self-Selection and Use of Gabapentin for Occasional Sleeplessness in an Over-the-Counter Environment
A Phase 3 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,254
- Enrollment target
NCT00659100 is a Phase 3 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 1,254 participants.
The verdict
NCT00659100, a Phase 3 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,254 participants
- Enrollment target
Study Summary
The purpose of this study is to assess consumers' behaviors related to gabapentin self- selection and use, relative to warnings and directions for use, as described in the proposed over-the-counter (OTC) product label.
Interventions
- DRUG Gabapentin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,254 participants |
| Start Date | 2006-08 |
| Est. Completion | 2007-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00659100
The ClinicalTrials.gov registry entry for NCT00659100 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,254 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gabapentin is the first listed.
NCT00659100 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00659100 about?
NCT00659100 is a clinical study titled "A Trial to Assess Consumer Self-Selection and Use of Gabapentin for Occasional Sleeplessness in an Over-the-Counter Environment". The purpose of this study is to assess consumers' behaviors related to gabapentin self- selection and use, relative to warnings and directions for use, as described in the proposed over-the-counter (OTC) product label.
What is the current status of trial NCT00659100?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,254 participants. The study started on 2006-08. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00659100?
The interventions under investigation include: Gabapentin (DRUG).
Who is sponsoring clinical trial NCT00659100?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.